112 related articles for article (PubMed ID: 20193330)
1. [Relationship of osteolytic biochemical indicators of bone metabolism with the therapeutic effect in breast cancer patients with bone metastases].
Li SF; Wang XR; Wang C; Chen Y; Ren L; Cui L; Tong ZS
Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):911-5. PubMed ID: 20193330
[TBL] [Abstract][Full Text] [Related]
2. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
3. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
[TBL] [Abstract][Full Text] [Related]
4. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer.
Vinholes J; Coleman R; Lacombe D; Rose C; Tubiana-Hulin M; Bastit P; Wildiers J; Michel J; Leonard R; Nortier J; Mignolet F; Ford J
Br J Cancer; 1999 Apr; 80(1-2):221-8. PubMed ID: 10390000
[TBL] [Abstract][Full Text] [Related]
5. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.
Tamiya M; Tokunaga S; Okada H; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Matsuura Y; Miyamoto N; Hattori M; Taira K; Daga H; Takeda K; Hirashima T
Clin Lung Cancer; 2013 Jul; 14(4):364-9. PubMed ID: 23276824
[TBL] [Abstract][Full Text] [Related]
7. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
8. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices.
Woitge HW; Pecherstorfer M; Li Y; Keck AV; Horn E; Ziegler R; Seibel MJ
J Bone Miner Res; 1999 May; 14(5):792-801. PubMed ID: 10320528
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
[TBL] [Abstract][Full Text] [Related]
10. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
[TBL] [Abstract][Full Text] [Related]
11. Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases.
Walls J; Assiri A; Howell A; Rogers E; Ratcliffe WA; Eastell R; Bundred NJ
Br J Cancer; 1999 Jun; 80(8):1265-70. PubMed ID: 10376982
[TBL] [Abstract][Full Text] [Related]
12. Can bone markers guide more effective treatment of bone metastases from breast cancer?
Clemons M; Cole DE; Gainford MC
Breast Cancer Res Treat; 2006 May; 97(1):81-90. PubMed ID: 16319976
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of cancer-induced bone diseases by bone metabolic marker].
Takahashi S
Clin Calcium; 2006 Apr; 16(4):581- 90. PubMed ID: 16582508
[TBL] [Abstract][Full Text] [Related]
14. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
Kobayashi Y; Ochi M; Tokue A
Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
[TBL] [Abstract][Full Text] [Related]
15. Normalisation of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancer.
Lüftner D; Richter A; Geppert R; Wernecke KD; Possinger K
Anticancer Res; 2003; 23(2A):1017-26. PubMed ID: 12820341
[TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen for diagnosis of bone metastases in patients with primary lung cancer.
Yokoyama T; Yamamoto M; Shima K; Suzuki K; Sako C; Ito G; Kume M; Maeda M
Respirology; 2005 Jun; 10(3):300-4. PubMed ID: 15955141
[TBL] [Abstract][Full Text] [Related]
17. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
[TBL] [Abstract][Full Text] [Related]
18. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of urine deoxypyridinoline for detecting bone metastases in breast cancer patients.
Hou MF; Lin SB; Yuan SS; Tsai LY; Tsai SM; Hsieh JS; Huang TJ
Ann Clin Lab Sci; 2003; 33(1):55-61. PubMed ID: 12661898
[TBL] [Abstract][Full Text] [Related]
20. Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas.
Oremek G; Sauer-Eppel H; Klepzig M
Anticancer Res; 2007; 27(4A):1961-2. PubMed ID: 17649805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
